Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation (AML)

This study has been withdrawn prior to enrollment.
(Adult patient population barriers.)
Sponsor:
Information provided by (Responsible Party):
Kenneth Lucas, University of Louisville
ClinicalTrials.gov Identifier:
NCT01483274
First received: November 3, 2011
Last updated: November 30, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: June 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)